Emily Speelmon
Pulmonary Disease · Dayton, OHNPI 1306003769
Payments from drug & device makers
Across 147 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$776
- AstraZeneca$609
- Boehringer Ingelheim$159
- Pulmonx Corporation$123
- Mylan Specialty L.p.$120
- Genentech USA, Inc.$115
- plus $671 from 19 others
What the payments were for
- Food & beverage$2,52798%
- Education$462%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $776 |
| AstraZeneca | 26 | $609 |
| Boehringer Ingelheim | 9 | $159 |
| Pulmonx Corporation | 4 | $123 |
| Mylan Specialty L.p. | 8 | $120 |
| Genentech USA, Inc. | 5 | $115 |
| Grifols USA, LLC | 5 | $93 |
| Insmed, Inc. | 4 | $88 |
| Regeneron Healthcare Solutions, Inc. | 4 | $70 |
| Inspire Medical Systems, Inc. | 2 | $65 |
| United Therapeutics Corporation | 2 | $42 |
| Merck | 2 | $38 |
| Actelion Pharmaceuticals US, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 2 | $28 |
| Ambu Inc. | 1 | $27 |
| Abiomed | 1 | $25 |
| Verona Pharma, Inc. | 1 | $22 |
| Advanced Respiratory, Inc | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Baxter Healthcare | 1 | $18 |
| Pfizer | 1 | $17 |
| Viatris Specialty LLC | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Sanofi | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,573 in reported general payments places this provider in the 50th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 388 | $348,354 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 188 | $127,607 |
| Breo ElliptaFluticasone/Vilanterol | 232 | $126,619 |
| Dupixent PenDupilumab | 29 | $119,207 |
| Dupixent SyringeDupilumab | 13 | $48,649 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $39,340 |
| Spiriva RespimatTiotropium Bromide | 30 | $31,099 |
| SymbicortBudesonide/Formoterol Fumarate | 77 | $21,459 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 27 | $20,208 |
| DuleraMometasone/Formoterol | 28 | $11,070 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $9,223 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 416 | $7,744 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 44 | $7,244 |
| Incruse ElliptaUmeclidinium Bromide | 16 | $5,881 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $5,675 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $776 | $525,171715 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $609 | $149,066265 claims |
| Boehringer IngelheimSpiriva Respimat, Stiolto Respimat | $159 | $51,30757 claims |
| MerckDulera | $38 | $11,07028 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Dayton
- Thomas YungerDayton$401K
- Daniel PearsonDayton$61K
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.